Last $57.93 USD
Change Today -0.91 / -1.55%
Volume 750.8K
MDVN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (MDVN) Snapshot

Open
$59.33
Previous Close
$58.84
Day High
$59.64
Day Low
$57.72
52 Week High
02/25/14 - $88.20
52 Week Low
06/21/13 - $44.51
Market Cap
4.4B
Average Volume 10 Days
1.2M
EPS TTM
$-0.58
Shares Outstanding
76.3M
EX-Date
07/27/99
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (MDVN)

medivation inc (MDVN) Related Businessweek News

No Related Businessweek News Found

medivation inc (MDVN) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.

370 Employees
Last Reported Date: 02/27/14

medivation inc (MDVN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $725.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $464.2K
Chief Commercial Officer
Total Annual Compensation: $425.0K
Compensation as of Fiscal Year 2012.

medivation inc (MDVN) Key Developments

Medivation Appoints Patrick Machado to Board of Directors

Medivation, Inc. announced that Patrick Machado has been appointed to the company's board of directors. Mr. Machado recently retired from his role as chief financial and business officer, and will formally retire from Medivation on April 18, 2014.

Regents of the University of California Files a Complaint Against Medivation, Inc. and Medivation Prostate Therapeutics, Inc

On April 11, 2014, The Regents of the University of California (UCLA) filed a complaint against Medivation, Inc. and its subsidiary Medivation Prostate Therapeutics, Inc. in the Superior Court of the State of California, County of San Francisco. The complaint arises from the parties’ 2005 Exclusive License Agreement which grants to MPT rights in certain UCLA patents, including the UCLA patents covering XTANDI. The complaint centers on two allegations. The first allegation is that Medivation and MPT have failed to pay UCLA 10% of ‘Operating Profits’ Medivation has received (and will continue to receive) from Astellas Pharma, Inc. as a result of the 2009 Collaboration Agreement between Medivation and Astellas. UCLA alleges that such Operating Profits are ‘Sublicensing Income’ under the ELA and that UCLA is entitled to 10% of such payments. The second allegation is that Medivation has breached its fiduciary duties to UCLA, as a minority shareholder of MPT. UCLA owns a fraction of 1% of the outstanding shares of MPT. The complaint seeks a declaration and judgment for breach of contract related to the allegation that ‘Operating Profits’ payments received from Astellas are ‘Sublicensing Income’ under the ELA, a judgment that Medivation has breached its fiduciary duties and an injunction requiring Medivation to comply with its fiduciary duties. The complaint does not seek termination of the ELA.

Astellas Pharma Inc. and Medivation Inc. Announce European Regulatory Submission for XTANDI (Enzalutamide) Capsules for Chemotherapy-Naive Metastatic Prostate Cancer

Astellas Pharma Inc. and Medivation Inc. announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. XTANDI is currently approved in Europe for the treatment of adult men with mCRPC whose disease has progressed on or after docetaxel chemotherapy. The European application is based on the results from the Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in more than 1,700 chemotherapy-naive mCRPC patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDVN:US $57.93 USD -0.91

MDVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $6.18 USD -0.12
Insys Therapeutics Inc $38.64 USD +1.88
InterMune Inc $28.29 USD -0.02
Sanofi India Ltd 2,952 INR +48.60
Seattle Genetics Inc $38.84 USD +0.27
View Industry Companies
 

Industry Analysis

MDVN

Industry Average

Valuation MDVN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.0x
Price/Book 57.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.